Genomictree Inc. (KOSDAQ: 228760)

Market Cap	388.51B
Revenue (ttm)	2.04B
Net Income (ttm)	-9.56B
Shares Out	23.98M
EPS (ttm)	-537.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	127,021
Open	16,240
Previous Close	16,200
Day's Range	16,240 - 17,050
52-Week Range	14,220 - 27,950
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2024

About Genomictree

Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B for detection of genetic and epigenetic markers associated with bladder cancer in hematuria patients. It also provides AccuraDTect SARS-CoV-2 RT-qPCR...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2000
• Employees: 81
• Stock Exchange: KOSDAQ
• Ticker Symbol: 228760

Financial Performance

In 2023, Genomictree's revenue was 3.42 billion, a decrease of -88.56% compared to the previous year's 29.87 billion. Losses were -8.76 billion, 32.1% more than in 2022.